Welcome to our dedicated page for Palomino Laboratories SEC filings (Ticker: PALX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Palomino Laboratories's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Palomino Laboratories's regulatory disclosures and financial reporting.
Palomino Laboratories Inc. reported first-quarter 2026 results as a pre-revenue, development-stage fabless semiconductor company focused on microLED-based optical interconnects. For the three months ended March 31, 2026, it recorded a net loss of $1,243,430, driven by operating expenses of $1,243,603, including $805,363 in general and administrative costs and $438,240 in research and development.
Cash and cash equivalents were $6,656,641 as of March 31, 2026, with total assets of $7,361,705 and stockholders’ equity of $7,009,735. The company remains pre-revenue but is building out lab equipment and facilities, recording $318,336 of capital spending in the quarter.
Subsequent to quarter-end, Palomino raised an additional $16,975,412 through April 2026 private placements of common stock and warrants, and management believes existing cash plus these proceeds will fund operations for at least one year from the financial statement issuance date. The company expects continued losses as it hires, advances R&D, and protects its intellectual property.
Palomino Laboratories Inc. completed a second and final closing of a private stock offering to accredited investors. The company sold 470,000 shares of common stock at $4.00 per share, raising gross proceeds of $1,880,000.00. This followed an initial closing of 3,773,853 shares for $15,095,412.00 at the same price.
The unregistered offering relied on Section 4(a)(2) and Rule 506 of the Securities Act. Placement agent Laidlaw & Company (UK) Ltd. received cash fees based on invested amounts and was granted 374,761 five-year warrants with a $4.80 exercise price and weighted-average anti-dilution protection.
Palomino Laboratories Inc. entered into subscription agreements for a private placement of its common stock. On April 20, 2026, the company sold 3,773,853 shares at $4.00 per share, raising $15,095,412 in an initial closing, with the Offering permitted to reach up to $30,000,000 through additional closings by April 30, 2026.
Laidlaw & Company (UK) Ltd. will receive cash fees and expense reimbursements based on gross proceeds, plus warrants equal to 10% of shares sold to its introduced investors at a 120% exercise price. Investors received registration rights requiring Palomino to file resale registration statements and provide piggyback rights, giving a pathway to eventual public resale of the privately placed shares.
Palomino Laboratories Inc. director and secretary Richard Ogawa made an open-market purchase of the company’s Common Stock. He bought 12,500 shares at $4.00 per share, increasing his direct holdings to 1,762,500 shares. This filing shows a modest increase in his personal investment stake.
Palomino Laboratories Inc. director Steven Denbaars made an open-market purchase of 12,500 shares of Common Stock at $4.00 per share on April 20, 2026. After this transaction, he directly owns 1,762,500 shares of the company’s Common Stock.